ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
Oncology
Prevalence
75.0 / 100K
Incidence
47.0 / 100K/yr
1 drug in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| Zidesamtinib | Nuvalent, Inc. (NUVL) |
Frequently asked questions
How many drugs are in development for ROS1-positive Non-Small Cell Lung Cancer (NSCLC)?
BioSniper tracks 1 drug in development for ROS1-positive Non-Small Cell Lung Cancer (NSCLC) across 1 company.
How many clinical trials target ROS1-positive Non-Small Cell Lung Cancer (NSCLC)?
There are 2 clinical trials targeting ROS1-positive Non-Small Cell Lung Cancer (NSCLC) tracked by BioSniper.
What is the prevalence of ROS1-positive Non-Small Cell Lung Cancer (NSCLC)?
The estimated prevalence of ROS1-positive Non-Small Cell Lung Cancer (NSCLC) is approximately 75.0 per 100,000 population.
Deep-dive into ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis